

# Sarcomatrix has been crowned the Regional Champion of the Pegasus Startup World Cup Competition

*Advances to Grand Finale for \$1M Grand Prize in San Francisco*

**SARCOMATRIX**  
Saving Lives by Restoring Muscles

RENO, NV, UNITED STATES, September 20, 2024 /EINPresswire.com/ --

Sarcomatrix, a pioneering leader in muscle disease therapy innovation, is proud to announce that it has been named the Regional Champion of the Pegasus Startup World Cup Competition, held during Reno StartUp Week. This significant achievement earns Sarcomatrix a coveted spot at the Startup World Cup Grand Finale, where it will compete for a \$1 million grand prize on October 4, 2024, at the Hilton Union Square in San Francisco.

“

“We are thrilled to have been named Regional Champion and to advance to the Startup World Cup Grand Finale,” said David R. Craig, CEO of Sarcomatrix Therapeutics.”

*David Craig, CEO*

This victory underscores the groundbreaking work that Sarcomatrix is undertaking in the biotech space, with a focus on developing cutting-edge treatments for [muscle diseases](#). Competing against a talented field of startups, Sarcomatrix was recognized for its innovative approach and its potential to transform the treatment landscape for muscle-related disorders.

“We are thrilled to have been named Regional Champion and to advance to the Startup World Cup Grand Finale,” said David R. Craig, CEO of Sarcomatrix Therapeutics. “This achievement is a testament to our team’s dedication and the potential of our therapies to make a real difference in the lives of patients. We look forward to representing Sarcomatrix on the global stage and continuing to push the boundaries of what’s possible in muscle disease treatment.”

The Startup World Cup, organized by Pegasus Tech Ventures, is one of the most prestigious startup competitions globally, bringing together the most promising startups from across the world to compete for the \$1 million investment prize. The competition is a platform for showcasing innovation, entrepreneurship, and visionary solutions that have the power to shape the future.

As Sarcomatrix moves toward the Grand Finale, the team expresses deep gratitude for the continued support from partners, investors, and the broader community. This journey represents a critical step forward in the company's mission to develop life-changing therapies for muscle diseases, and Sarcomatrix is excited to share future updates on its progress.

About Sarcomatrix:

Sarcomatrix is a biotechnology company committed to revolutionizing the treatment of muscle diseases. Through innovative research and a deep understanding of muscle biology, Sarcomatrix is developing groundbreaking therapies aimed at improving patient outcomes and quality of life. The company's lead molecule, S-969, is currently in preclinical development, targeting critical pathways involved in muscle regeneration and repair.

David R Craig

Sarcomatrix Therapeutics Corp.

+1 415-246-3311

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/745192668>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.